Prognostic value of the TyG index for in-hospital mortality in nondiabetic COVID-19 patients with myocardial injury


Biter H. İ., Kalyoncuoğlu M., Tosu A. R., Çakal S., Apaydın Z., Gümüşdağ A., ...Daha Fazla

Revista da Associacao Medica Brasileira, cilt.68, sa.9, ss.1297-1302, 2022 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 68 Sayı: 9
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1590/1806-9282.20220410
  • Dergi Adı: Revista da Associacao Medica Brasileira
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Sayfa Sayıları: ss.1297-1302
  • Anahtar Kelimeler: Triglyceride, COVID-19, Myocardial, Damage
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

OBJECTIVE: The purpose of this study was to explore the efficacy of the triglyceride glucose (TyG) index on in-hospital mortality in nondiabetic coronavirus disease 2019 (COVID-19) patients with myocardial injury. METHODS: This was a retrospective study, which included 218 nondiabetic COVID-19 patients who had myocardial injury. The TyG index was derived using the following equation: log [serum triglycerides (mg/dL) ×fasting blood glucose (mg/dL)/2]. RESULTS: Overall, 49 (22.4%) patients died during hospitalization. Patients who did not survive had a higher TyG index than survivors. In multivariate Cox regression analysis, it was found that the TyG index was independently associated with in-hospital death. A TyG index cutoff value greater than 4.97 was predicted in-hospital death in nondiabetic COVID-19 patients with myocardial damage, with 82% sensitivity and 66% specificity. A pairwise evaluation of receiver operating characteristic (ROC) curves demonstrated that the TyG index (AUC: 0.786) had higher discriminatory performance than both triglyceride (AUC: 0.738) and fasting blood glucose (AUC: 0.660) in predicting in-hospital mortality among these patients. CONCLUSIONS: The TyG index might be used to identify high-risk nondiabetic COVID-19 patients with myocardial damage.